X4 Pharmaceuticals (XFOR) Gets a Buy From Piper Sandler
Buy Rating Affirmed on X4 Pharmaceuticals: A Comprehensive Analysis of Financial Stability and Drug Development Progress
X4 Pharmaceuticals Analyst Ratings
X4 Pharmaceuticals Analyst Ratings
X4 Pharmaceuticals (XFOR) Gets a Buy From Piper Sandler
Optimistic Buy Rating for X4 Pharmaceuticals Following FDA Approval and Strong Clinical Prospects
X4 Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for X4 Pharmaceuticals' Xolremdi on Robust Clinical Efficacy and Favorable Market Strategy
X4 Pharmaceuticals Analyst Ratings
Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects
B. Riley Securities Downgrades X4 Pharmaceuticals to Neutral, Lowers Price Target to $1
X4 Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), X4 Pharmaceuticals (XFOR) and Dynatronics (DYNT)
Promising Future for X4 Pharmaceuticals: Strong Financials and Potential Drug Launch Drive Buy Rating
TD Cowen Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)
X4 Pharmaceuticals (XFOR) Receives a Buy From B.Riley Financial
B. Riley Trims X4 Pharmaceuticals' Price Target to $3 From $4, Keeps Buy Rating
X4 Pharmaceuticals Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on X4 Pharmaceuticals (XFOR)
Stifel Nicolaus Remains a Buy on X4 Pharmaceuticals (XFOR)